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Augmented Reduced-Intensity Regimen Does Not
Improve Postallogeneic Transplant Outcomes in
Acute Myeloid Leukemia
Charles Craddock, MD1,2; Aimee Jackson, Bsc2; Justin Loke, MD1; Shamyla Siddique, Bsc2; Andrea Hodgkinson, PhD2; JohnMason, Bsc2;
Georgia Andrew, Bsc3; Sandeep Nagra, MBChB1; Ram Malladi, MD4; Andrew Peniket, MD5; Maria Gilleece, MD6; Rahuman Salim, MD7;
Eleni Tholouli, MD8; Victoria Potter, MD9; Charles Crawley, MD4; Keith Wheatley, DPhil2; Rachel Protheroe, MD10; Paresh Vyas, MD5;
Ann Hunter, MD11; Anne Parker, MD12; Keith Wilson, MD13; Jiri Pavlu, MD14; Jenny Byrne, MD15; Richard Dillon, MD16;
Naeem Khan, PhD3; Nicholas McCarthy, PhD3; and Sylvie D. Freeman, MD3
abstract
PURPOSE Reduced-intensity conditioning (RIC) regimens have extended the curative potential of allogeneic
stem-cell transplantation to older adults with high-risk acute myeloid leukemia (AML) andmyelodysplasia (MDS)
but are associated with a high risk of disease relapse. Strategies to reduce recurrence are urgently required.
Registry data have demonstrated improved outcomes using a sequential transplant regimen, fludarabine/
amsacrine/cytarabine-busulphan (FLAMSA-Bu), but the impact of this intensified conditioning regimen has not
been studied in randomized trials.
PATIENTS AND METHODS Two hundred forty-four patients (median age, 59 years) with high-risk AML (n5 164)
or MDS (n5 80) were randomly assigned 1:1 to a fludarabine-based RIC regimen or FLAMSA-Bu. Pretransplant
measurable residual disease (MRD) was monitored by flow cytometry (MFC-MRD) and correlated with outcome.
RESULTS There was no difference in 2-year overall survival (hazard ratio 1.05 [85% CI, 0.80 to 1.38] P5 .81) or
cumulative incidence of relapse (CIR) (hazard ratio 0.94 [95%CI, 0.60 to 1.46] P5 .81) between the control and
FLAMSA-Bu arms. Detectable pretransplant MFC-MRD was associated with an increased CIR (2-year CIR
41.0% v 20.0%, P5 .01) in the overall trial cohort with a comparable prognostic impact when measured by an
unsupervised analysis approach. There was no evidence of interaction between MRD status and conditioning
regimen intensity for relapse or survival. Acquisition of full donor T-cell chimerism at 3 months abrogated the
adverse impact of pretransplant MRD on CIR and overall survival.
CONCLUSION The intensified RIC conditioning regimen, FLAMSA-Bu, did not improve outcomes in adults
transplanted for high-risk AML or MDS regardless of pretransplant MRD status. Our data instead support the
exploration of interventions with the ability to accelerate acquisition of full donor T-cell chimerism as a tractable
strategy to improve outcomes in patients allografted for AML.
J Clin Oncol 00. © 2020 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License
INTRODUCTION
Allogeneic stem-cell transplantation (allo-SCT) is an
increasingly important treatment modality in adults with
acute myeloid leukemia (AML) and myelodysplasia
(MDS). The advent of reduced-intensity conditioning
(RIC) regimens has permitted the extension of a po-
tentially curative graft-versus-leukemia (GVL) effect to
older patients in whom transplantation using myeloa-
blative conditioning (MAC) is precluded by excess
toxicity.1 Indeed, the majority of allografts performed in
the United States now use an RIC regimen.
In patients with AML and MDS, the use of an RIC
regimen is associated with a higher rate of disease
relapse than is observed with myeloablative trans-
plants.2 Despite the fact that relapse remains the
dominant cause of transplant failure, no effective
strategies have yet been identified to reduce the risk of
disease recurrence after an RIC allograft. Indeed,
although a multiplicity of RIC regimens have been
developed, most using a fludarabine backbone,3,4
there have been very few randomized studies to in-
form choice of regimen, and as a result, clinical
practice worldwide is heterogeneous. Single-arm
studies using a sequential fludarabine/amasacrine/
cytarabine regimen, in which amsacrine-based cyto-
reductive chemotherapy is delivered 7-14 days prior to
a conventional RIC allograft incorporating either low
dose total body irradiation or busulphan (Bu), have
been reported to reduce the risk of relapse in high-risk
AML.5-7 However, despite the widespread adoption of
this regimen in the management of high-risk AML, its
benefits have never been examined in a randomized
trial.
The presence of measurable residual disease (MRD)
measured by flow cytometry, quantitative polymerase
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sequencing (NGS) is an important determinant of disease
relapse in adults with AML treated with intensive
chemotherapy.8-15,16 Although retrospective studies have
shown that the presence of pretransplant MRD is associ-
ated with an increased risk of relapse post-transplant,17-30
the reported effect size varies widely and prospective
studies addressing the prognostic value of pretransplant
flow cytometric MRD, the most commonly used and widely
applicable AML MRD technology, are lacking. Hourigan
et al31 recently reported that the presence of pretransplant
MRD in the peripheral blood, determined by an innovative
but currently research-restricted NGS strategy, was asso-
ciated with an increase in relapse in recipients of RIC but
not MAC regimens, but this study did not examine the
impact of flow-determined pretransplant MRD on outcome.
The FIGARO trial compared the outcomes of patients with
high-risk AML and MDS transplanted using an intensified
FLAMSA-Bu regimen with those receiving a conventional
fludarabine-based RIC regimen. The impact of flow cyto-
metric MRD on transplant outcomes was prospectively
determined in trial patients.
PATIENTS AND METHODS
Study Design
FIGARO, an open label phase II randomized trial, was
performed in 20 UK transplant centers and recruited pa-
tients from October 2013 to February 2017. The trial
Protocol (online only; EudraCT 2012-005538-12) was
approved by the UK research ethics service, National
Research Ethics Service (NRES). An independent data
monitoring committee oversaw the trial. Patients were
randomly assigned in a one-to-one ratio via a minimization
algorithm stratified by underlying disease, cytogenetic risk
group, disease status at transplant, intended control
transplant regimen, age, and donor type.
Patients
Patients were eligible for trial entry if they had a WHO-
defined diagnosis of AML or high-risk MDS, were under-
going their first allo-SCT from a matched sibling or unre-
lated donor, and had been deemed ineligible for a MAC
regimen on the grounds of age or comorbidity. Patients
were of age 22 to 75, had a Hematopoietic Cell Transplant-
Comorbidity Index (HCT-CI) score of 0-6, and were
transplanted using peripheral blood– or bone marrow
(BM)–derived stem cells from an HLA identical (HLA-A/-B/-
C/-DRbeta1) matched sibling or $ 7/8 HLA-A/-B/-C/-
DRbeta1 adult-unrelated donor. All patients with AML
were in complete remissions (CR1 and CR2) or had primary
refractory AML (defined by failure to achieve a morpho-
logical CR after two courses of induction chemotherapy).
High-risk MDSwas defined as patients with an International
Prognostic Scoring System score of intermediate-1 with .
5% blasts or intermediate-2 or high risk who had , 5%
blasts at the time of random assignment. Cytogenetic risk
group was classified as described previously.32
Conditioning Regimens and GVHD Prophylaxis
Patients were randomly assigned 1:1 to a control arm
determined by the investigator’s choice of Flu/B2/anti-
thymocyte globulin (ATG), Flu/Mel/alemtuzumab (A), or
Flu/Bu2/A (details given in the Data Supplement, online
only) versus an experimental arm of FLAMSA-Bu (Flu,
cytarabine [araC] 2 g/m2 once a day 3 4 days, amsacrine
[AMSA] 100 mg/m2 once a day 3 4 days, intravenous Bu
total dose 11.2 mg/kg) and ATG 5 mg/kg over 3 days.
Patients of age . 60 years received an adjusted FLAMSA-
Bu regimen using a reduced dose of araC (1 g/m2 once a
day3 4 days) and Bu (8mg/kg total). However, after the first
31 patients had received treatment on the experimental
arm, additional safety information was published with
regard to the FLAMSA-Bu regimen in patients of age $
CONTEXT
Key Objective
The FIGARO study is the first prospective trial to examine the impact of an intensified conditioning regimen (FLAMSA-Bu)
alongside the impact of pretransplant flow cytometric measurable residual disease (MRD) on transplant outcome in
patients allografted for acute myeloid leukemia (AML) or myelodysplasia (MDS).
Knowledge Generated
The results of FIGARO demonstrate that pretransplant flow cytometric MRD is correlated with an increased risk of disease
relapse after a reduced-intensity allograft by both conventional and unsupervised MRD analyses. Random assignment to
an intensified sequential conditioning regimen failed to improve transplant outcome regardless of pretransplant MRD
status.
Relevance
Our data do not support the use of an intensified sequential conditioning regimen as a strategy to improve transplant
outcome, regardless of pretransplant MRD status. The results further demonstrate the importance of flow cytometry-
determined MRD as a pretransplant risk characteristic in patients with AML or high-risk MDS.
2 © 2020 by American Society of Clinical Oncology
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60 years. The experimental regimen in the subsequent
77 patients was modified to Flu, araC 1 g/m2 once a day
3 4 days, AMSA 100 mg/m2 once a day3 4 days, and Bu
6.4 mg/kg for those patients who were . 60 years.
All patients received ciclosporin graft-versus-host-disease
(GVHD) prophylaxis. Supportive care was according to
institutional guidelines. All patients were formally reviewed
at day 1 100, 6, and 12 months post-transplant. BMs to
determine remission status were reviewed at day1 42, and
months 3, 6, 9, and 12 post-transplant. T-cell lineage
chimerism was assessed at months 3, 6, 9, and 12 post-
transplant.
MRD Quantitation
BMs for multiparameter flow cytometric (MFC) detection of
MRD were obtained pretransplant (within 4 weeks of
transplant) and at day 1 42 post-transplant. Sample lo-
gistics, processing, and analysis strategy are provided in the
Data Supplement. MFC-MRD analysis was performed
centrally, using a standardized manual gating strategy that
screened blasts for different-from-normal leukemia-
associated immunophenotypes (LAIPs) and any previ-
ously identified baseline LAIPs when available. Samples
were reported as MRD-negative if no baseline and/or
different-from-normal LAIP cells could be quantitated
above the limit of detection (approximately 0.02%-0.05%).
The results were not reported to treating clinicians.
Recognizing the potential for variation in manual MFC-MRD
analysis, an unsupervised approach was applied as an in-
dependent measurement of LAIPs. This incorporated (1) a
multidimensional clustering algorithm to maximize informa-
tion from the LAIP marker combinations and (2) statistical
criteria to discriminate blast subpopulations that were
immunophenotypically most aberrant (compared with refer-
ence ranges established from 40 control BMs) and above the
limit of quantitation (Data Supplement). The analytic method,
similar to standard different-from-normal MFC-MRD, did not
require diagnostic samples. Unsupervised MFC-MRD per-
centages were higher than conventional MFC-MRD as the
former summated all quantifiable nonoverlapping abnormal
blast subpopulations from an antibody combination, whereas
conventional MFC-MRD values are from a single LAIP.
Concordance between methods was strongest at higher MRD
levels (Data Supplement). The unsupervised MFC-MRD
combined test criteria included results from a third anti-
body combination (stem and progenitor) in addition to
standard LAIP markers; positivity required detection of ab-
errant blasts in at least two of the three antibody combinations
(Data Supplement).
Outcomes
The primary outcome was overall survival (OS) defined on
an intention-to-treat basis. A sensitivity analysis was con-
ducted to assess OS in a per-protocol population. Sec-
ondary outcome measures included event-free survival
(EFS), cumulative incidence of relapse (CIR), incidence of
GVHD, and transplant-related mortality (TRM). Acute and
chronic GVHD were scored according to published
criteria.33,34 Nonhematological grade 3-4 adverse events
were classified according to Common Terminology Criteria
for Adverse Events Version 4.0.
Statistical Analysis
The sample size was calculated on the basis of previously
published data and clinical judgment. Assuming a 2-year
OS in the control arm of 25%, to detect a 15% improvement
in the experimental arm, a total of at least 214 patients (two-
sided a 5 0.15 and b 5 0.16) were required. To account
for the likelihood that 10% of randomly assigned patients
would not proceed to transplant, the trial aimed to recruit a
minimum of 240 patients. Analysis was conducted in line
with the predefined statistical analysis plan on the
intention-to-treat population unless otherwise stated. Per-
protocol population analysis was restricted to patients who
had commenced the conditioning regimen. Standard
analysis methods were employed as further outlined in the
Data Supplement.
Additional analysis in the per-protocol populations was
conducted to assess the effect on OS, CIR, and TRM of
pretransplant MRD by the different MFC-MRD analysis
methods and for various MRD thresholds. No adjustment
for multiple testing was made within the MRD threshold
analysis; however, the results are interpreted with caution
and focused on identifying the highest level of discrimi-
nation from a range of significant results.
RESULTS
Enrollment
Of 255 patients screened for trial entry, 244 fulfilled eli-
gibility criteria and were randomly assigned to receive trial
therapy (Fig 1). Twenty-eight randomly assigned patients
did not receive their allocated treatment (two deaths, 14
withdrawn because of clinical deterioration or patient or
physician choice, and 12 relapses prior to transplant). Of
the 108 patients who were transplanted on the control arm,
63 received Flu/B2/ATG, 31 Flu/Mel/A, and 14 Flu/B2/A.
The median follow-up was 35 months. Patient and trans-
plant characteristics of randomly assigned patients are
summarized in Table 1. One hundred sixty-four patients
had an initial diagnosis of AML of whom 154 were in CR1 or
CR2 and nine had primary refractory AML at the time of
random assignment. Eighty patients had high-risk MDS.
The median age of the study population was 59 years
(range, 22-75 years).
Survival
The 2-year OS was 58.8% in patients treated on the control
arm and 60.9% in patients assigned to FLAMSA-Bu
(hazard ratio [HR] 1.05 [85% CI, 0.80 to 1.38] log-rank
P value5 .81; Fig 2A). The EFS at 2 years was 48.7% in the
Journal of Clinical Oncology 3
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control arm versus 54.2% for FLAMSA-Bu (HR 0.96 [95%
CI, 0.68 to 1.35] log-rank P value5 .82; Fig 2B). Two-year
OS and EFS were similar between both arms in a per-
protocol sensitivity analysis (Data Supplement). In the
preplanned subgroup analysis, no survival benefit of the
FLAMSA-Bu regimen was evident in patients diagnosed
with either AML or MDS, in patients with AML according to
cytogenetic risk category, or in patients under or over 60
years of age. No difference in outcome was evident when
analysis was restricted to patients over 60 in the experi-
mental arm after adoption of the protocol amendment.
Transplant-Related Mortality, GVHD, and
Disease Relapse
The 1-year TRM was 16.8% in the control arm and 20.5%
in the experimental arm (HR 1.20 [95% CI, 0.68 to 2.13],
Gray’s test P value 5 .53). There were no statistically
significant differences in the cumulative incidences of
acute GVHD at day 1 100 (with death and relapse as
competing events) between the control and FLAMSA-Bu
arms (grades 2-4, 10.1% v 8.3%, Gray’s test P value5 .93;
grade 3-4, 1.7% v 5.8%, Gray’s test P value 5 .23). The
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FIG 1. Trial CONSORT diagram. FBA, fludarabine/busulphan/alemtuzumab; FB-ATG, fludarabine/busul-
phan/antithymocyte globulin; FMA, fludarabine/melphalan/alemtuzumab; FLAMSA-Bu, fludarabine/amsa-
crine/cytarabine-busulphan.
4 © 2020 by American Society of Clinical Oncology
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25.2% and 19.2% in the control and FLAMSA-Bu arms,
respectively (Gray’s test P value 5 .53). Twenty-eight pa-
tients received DLI in the control arm (19 for mixed chi-
merism from day 1 115, nine for relapse) and 14 in the
experimental arm (10 for mixed chimerism from day1 104,
four for relapse) (Data Supplement). There was no evi-
dence of DLI impact on the incidence of GVHD with eight
and five episodes of chronic GVHD post-DLI in the control
and FLAMSA-Bu arms, respectively.
The 2-year CIR was 29.5% in patients in the control arm
and 26.7% in patients assigned FLAMSA-Bu (Fig 2C)
(Gray’s test P value 5 .81). There was no statistically
significant effect of disease (AML v MDS), patient age, and








Age # 60 years 71 (58) 69 (57) 140 (57)
. 60 years 51 (42) 53 (43) 104 (43)
Sex Female 51 (42) 48 (39) 99 (41)
Male 71 (58) 74 (61) 145 (59)
HCT-comorbidity index # 2 66 (57) 79(68) 145 (62)
$ 3 33 (28) 18 (15) 51 (22)
Unknown 23(19) 25(20) 48 (20)
Diagnosis AML 82 (67) 82 (67) 164 (67)
MDS 40 (33) 40 (33) 80 (33)
AML cytogenetic risk Adverse 24 (29) 26 (32) 50 (30)
Intermediate 53 (65) 52 (63) 105 (64)
Favourable 4 (5) 3 (4) 7 (4)
Unknown 1 (1) 1 (1) 2 (1)
AML disease status CR1 or CR2 77 (94) 77 (94) 154 (94)
Primary refractory 5 (6) 4 (5) 9 (5)
Unknown 0 1 (1) 1 (1)
AML FLT3-ITD Yes 20 (24) 23 (28) 43 (26)
No 49 (60) 52 (63) 101(62)
Unknown 13 (16) 7 (9) 20 (12)
AML-mutated NPM1 Yes 17 (21) 23 (28) 40 (24)
No 50 (61) 53 (65) 103 (63)
Unknown 15 (18) 6 (7) 21 (13)
MDS IPSS # 2 33 (83) 33 (83) 66 (83)
. 2 0 (0) 2 (5) 2 (3)
Unknown 7 (18) 5 (13) 12 (15)
Transplant
Donor type Sibling 25 (20) 24 (20) 49 (20)
Unrelated 97 (80) 98 (80) 195 (80)
Graft type PBSCs 101 (94) 107 (99) 208 (96)
BM 7 (6) 1 (1) 8 (4)
Pretransplant MFC-MRD status Positive 43 (35) 52 (43) 95(39)
Negative 46 (38) 35 (29) 81 (33)
Inadequate 14 (11) 13 (11) 27 (11)
No sample 19 (16) 22 (18) 41 (17)
Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; CR, complete remission; FBA, fludarabine/busulphan/alemtuzumab; FB-ATG,
fludarabine/busulphan/antithymocyte globulin; FLAMSA-Bu, fludarabine/amsacrine/cytarabine-busulphan; FMA, fludarabine/melphalan/alemtuzumab;
HCT-CI, hematopoietic cell transplant-comorbidity index; IPSS, International Prognostic Scoring System; ITD, internal tandem duplication; PBSC, peripheral
blood stem cells; MDS, myelodysplasia; MFC, multiparameter flow cytometric; MRD, minimal residual disease.
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treatment arm (including by different control regimens) on
relapse risk (Data Supplement).
Pretransplant MRD Status and Post-Transplant Outcome
Pretransplant MRD data, excluding inadequate BMs, were
available in 176 randomly assigned patients of whom 156
proceeded to transplant (Data Supplement, distribution of
clinical characteristics by MRD status in Data Supplement).
MRD at any level was detected by flow cytometry in 43% of
the 156 patients (38 of 79 receiving control regimens and 29
of 77 receiving FLAMSA-Bu) (median MRD level of 0.2%,
range 0.02%-12.3%). In randomly assigned patients, pre-
transplant MRD positivity was associated with an increased
relapse risk (2-year CIR 41.0% v 20.0% (HR 1.97 [95% CI,
1.18 to 3.28], Gray’s test P value 5 .01) and a borderline
significant reduction in 2-year OS (70.1%-51.4% log-rank
P value5 .05) (Data Supplement). No statistically significant
difference was observed in TRM (2-year TRM 12.1% MRD-
positive v 21.6% MRD-negative (HR 0.60 (95% CI, 0.29 to
1.27), Gray’s test P value 5 .18). There was no interaction
between MRD status and conditioning intensity in the pre-
planned subgroup survival analysis (heterogeneity test P 5
.56) or on relapse risk (treatment MRD interaction term P5
.92). No difference in post-transplant MRD clearance was
apparent between treatment arms from MRD results at
day 1 42 (Data Supplement). Although flow cytometric
methodology represents the most widely applicable MRD
assay in AML, its reliance on operator analysis expertise is a
recognized limitation that may potentially contribute to
variation in its prognostic value.27 We therefore used an
unsupervised computational approach to analyze flow
cytometric sample files to obtain independent evaluation of
the impact of conventionally determined MFC-MRD (Data
Supplement) on outcome in the transplanted cohort. Twenty
patients with pretransplant conventional MFC-MRD results
were excluded since their samples had fewer than the
minimum requirement of 1,000 blast events. Outcomes
(Table 2, Fig 3) and test accuracy for relapse prediction
(Data Supplement) were comparable between bothmethods
in transplanted patients, supporting reproducibility of the
prognostic effect from immunophenotypic MRD. The
prognostic significance of pretransplant MRD above the
thresholds that provided the most discrimination in this RIC
allo-SCT setting (0.2% by conventional analysis, 1% by
unsupervised) (Fig 3B-C, Table 2) was retained for relapse in
an analysis adjusted for additional factors with the potential
to determine transplant outcome (Table 2). To further test
the robustness of these MFC-MRD–predicted outcomes, we
applied stringent criteria (quantifiable, unsupervised MFC-
MRD in at least 2 different antibody combinations) to select
OS
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B
FIG 2. (A) OS, (B) EFS, and (C) CIR by conditioning regimen in the intention-to-treat population. 85% CIs are reported for overall survival to align with the
type I error rate applied in the sample size calculation (described in the Data Supplement). CIR, cumulative incidence of relapse; EFS, event-free survival;
FLAMSA-Bu, fludarabine/amsacrine/cytarabine-busulphan; HR, hazard ratio; OS, overall survival.
6 © 2020 by American Society of Clinical Oncology
Craddock et al
Downloaded from ascopubs.org by UNIVERSITY BIRMINGHAM on January 4, 2021 from 147.188.216.055
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
patients with the most extensive immunophenotypic blast
aberrancies. Most patients with test positivity by these criteria
had conventional MRD levels $ 0.2% (Data Supplement).
The 2-year CIR after transplant for patients with a positive test
was 50.5% compared with 20.6% for patients with a neg-
ative or equivocal test (Gray’s test P value , .001) (Fig 3D,
Table 2), and the overall accuracy for relapse prediction was
73% (Data Supplement).
Chimerism and Transplant Outcome
To explore the contribution of a putative GVL effect to post-
transplant outcome, we studied the impact of acquisition of
full donor T-cell chimerism (FDTCC) on transplant out-
come. Acquisition of FDTCC was similar in control and
experimental arms and not affected by pretransplant MRD
status (Data Supplement). Acquisition of FDTCC at
3 months post-transplant was associated with lower CIR
(Gray’s test P value, .001) with 2-year CIR in patients with
FDTCC of 13.1% (95% CI, 7.3 to 20.5) compared with
44.8% (95% CI, 30.0 to 58.3) (Data Supplement). In
patients with pretransplant MRD positivity, acquisition of
FDTCC at 3 months post-transplant was associated with a
comparable outcome with that achieved by patients without
detectable pretransplant MRD (Fig 4).
DISCUSSION
Strategies with the potential to reduce the risk of relapse in
patients with AML or MDS transplanted using RIC include
both intensification of the antitumor properties of the
conditioning regimen35 and optimization of the GVL effect.5
The cytoreductive properties of distinct RIC regimens vary
considerably, and relapse rates ranging from 30% to 60%
have been reported in patients using commonly adopted
transplant protocols.3,36 In unrandomized phase II trials
and retrospective registry data, the FLAMSA-Bu protocol,
which incorporates additional cytoreductive chemotherapy
prior to a fludarabine-based RIC regimen, has been re-
ported to reduce relapse and improve outcome in high-risk
AML or MDS and as a consequence has become widely
adopted despite its attendant substantially increased in-
patient stay and potential toxicity.5-7 Our data, however,
show no impact on either relapse rate or survival in patients
transplanted using this intensified regimen. Differences in
control regimens and age-related FLAMSA-Bu dose ad-
justments constitute potential limitations to this analysis,
but we did not detect a differential effect on outcomes from
any of these variables. Of particular note, FLAMSA-Bu did
not result in improved survival in predefined subgroups
including patients with an adverse-risk karyotype.
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21.4% (14 to 29.8) , .001 2.52 (1.3 to 4.9)
.006
17.8% (11 to 25.9) .35 66.2% (56.1 to 74.6) .11 1.41 (0.77 to 2.58)
.28
UnSup MRD $ 1%
n 5 33





20.6% (13.3 to 28.9) , .001 2.44 (1.25 to 4.74)
.009





50.5% (32.2 to 66.2) 12% (3.7 to 25.5) 51.7% (33.7 to 67)
NOTE. Conventional and unsupervised (computational) MRD comparisons are in transplanted patients. Adjusted results are the results of cox proportional
hazard models adjusted for age, cytogenetic risk, FLT3-ITD presence, treatment arm, and HCT comorbidity.
Abbreviations: CIR, cumulative incidence of relapse; HR, hazard ratio; MRD, measurable residual disease (flow cytometric); UnSup, unsupervised
(computational) MRD analysis; UnSup-combined MRD, unsupervised MRD applying criteria of MRD-positive5 aberrant blasts in at least 2 of the 3 antibody
combinations (standard and stem cell), MRD-negative or equivocal 5 aberrant blasts in 0-1 of 3 antibody combinations; TRM, transplant-related mortality.
Journal of Clinical Oncology 7
Outcomes From RIC Intensification in AML With Pretransplant MRD
Downloaded from ascopubs.org by UNIVERSITY BIRMINGHAM on January 4, 2021 from 147.188.216.055
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
In exploratory studies, pretransplant MRD, measured using
a widely used flow cytometric methodology, was pro-
spectively examined as a prognostic determinant of
transplant outcome. Pretransplant MRD status was iden-
tified as an important prognostic factor for relapse in
multivariable analysis, confirming previous retrospective
analyses. However, although the US CTN 0901 trial
identified the presence of NGS-determined pretransplant
MRD as a predictor of outcome in patients transplanted
using a reduced intensity but not a MAC regimen,31 in the
FIGARO trial, we observed no benefit accruing in MRD-
positive patients from intensification of RI conditioning. Of
interest, the risk of relapse after transplant in the RIC arm of
US-CTN 0901 (48% at 18 months2) was strikingly higher
than that observed in the FIGARO trial despite both trials
using similar RIC regimens.
One of the major limitations of the widely used flow cyto-
metric MRD assays has been the inevitable subjectivity from
manual gating of immunophenotypic raw data. Using a
novel unsupervised analysis approach as independent
evaluation of conventional flow cytometric MRD, we were
able to confirm the reproducibility of the prognostic signif-
icance of immunophenotypic pretransplant MRD in this
older age group typically considered for RIC regimens. In-
corporating comprehensive genetic information for genetic
subtype MRD interpretation (such as FLT3-ITD29,31), con-
sideration of under-representation of MRD from hemodi-
lution or hypoplasia and potentially MRD as a continuous
variable will further progress refining and validating flow
cytometric MRD thresholds for transplant decision making.
There is much debate concerning the benefit of an RIC
allograft in patients with evidence of pretransplant MRD. It
is therefore of interest that approximately 50% of FIGARO
patients with evidence of pretransplant MRD did not re-
lapse, confirming the validity of transplantation using an
RIC regimen as a therapeutic strategy in high-risk AML—
even in patients with detectable MRD. There is compelling
evidence of a potent GVL effect in patients with AML
allografted using an RIC regimen.37 The observation that
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FIG 3. (A) CIR by conventional MFC-MRD status, (B) CIR by conventional MFC-MRD with 0.2% cutoff, (C) CIR by unsupervised (computational) MFC-MRD
with 1% cutoff, (D) CIR by unsupervised (computational) combined MFC-MRD test status. Impact of flow cytometric MRD on outcomes of transplanted
patients are shown with comparison of results from conventional and unsupervised (computational) analysis approaches. Unsupervised MFC-MRD cutoff is
higher than conventional MFC-MRD as the former values summate all quantifiable nonoverlapping abnormal blast subpopulations from an antibody
combination, whereas conventional MFC-MRD values are from a single LAIP. UnSup-combined MRD is unsupervised MRD applying criteria of MRD-positive
5 aberrant blasts in at least two of the three antibody combinations (standard and stem cell) and MRD-negative or equivocal 5 aberrant blasts in 0-1 of 3
antibody combinations. CIR, Cumulative incidence of relapse; LIAP, leukemia-associated immunophenotype; MFC-MRD, flow cytometric measurable
residual disease; UnSup, unsupervised (computational) MRD analysis.
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pretransplant MRD was mitigated by the acquisition of
FDTCC at 3 months requires further prospective exami-
nation and identifies optimization of the GVL effect as an
important approach to improve outcome in patients
transplanted using an RIC regimen. Such strategies include
using a T replete graft, a rapid taper of post-transplant
immunosuppression, or early administration of pharma-
cological agents such as azacitidine, decitabine,38-40 or DLI.
AFFILIATIONS
1Centre for Clinical Haematology, Queen Elizabeth Hospital,
Birmingham, United Kingdom
2Cancer Research UK Clinical Trials Unit, University of Birmingham,
United Kingdom
3Institute of Immunology and Immunotherapy, University of Birmingham,
United Kingdom.
4Addenbrookes Hospital, Cambridge, United Kingdom
5Churchill Hospital, Oxford, United Kingdom
6St James’s Hospital, Leeds, United Kingdom
7Royal Liverpool University Hospital, United Kingdom
8Manchester Royal Infirmary, Manchester, United Kingdom
9Kings College Hospital, London, United Kingdom
10Bristol Haematology and Oncology Centre, United Kingdom
11Leicester Royal Infirmary, United Kingdom
12Queen Elizabeth University Hospital, Glasgow, United Kingdom
13University Hospital Wales, United Kingdom
14Imperial College Hospital, London, Unite Kingdom
15Centre for Clinical Haematology, Nottingham, United Kingdom
16Department of Medical and Molecular Genetics, King’s College,
London, United Kingdom
CORRESPONDING AUTHOR
Charles Craddock, MD, Centre for Clinical Haematology, Queen Elizabeth
Hospital, Birmingham B15 2TH; e-mail: Charles.Craddock@uhb.nhs.uk.
SUPPORT
Supported by Blood Cancer UK and Cure Leukemia. Pierre Fabre and
Eurocept provided busulphan and amasacrine for trial purposes in
addition to unrestricted educational support.
CLINICAL TRIAL INFORMATION
FIGARO
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF
INTEREST
Disclosures provided by the authors are available with this article at DOI
https://doi.org/10.1200/JCO.20.02308.
AUTHOR CONTRIBUTIONS
Conception and Design: Charles Craddock, Aimee Jackson, Shamyla
Siddique, Sandeep Nagra, Andrew Peniket, Eleni Tholouli, Sylvie D.
Freeman, Keith Wheatley, Paresh Vyas, Ann Hunter
Administrative support: Shamyla Siddique
Provision of study material and patients: Sandeep Nagra, Ram Malladi,
Andrew Peniket, Maria Gilleece, Rahuman Salim, Eleni Tholouli, Victoria
Potter, Charles Crawley, Rachel Protheroe, Paresh Vyas, Ann Hunter,
Anne Parker, Jenny Byrne
Collection and assembly of data: Charles Craddock, Aimee Jackson, Justin
Loke, Andrea Hodgkinson, John Mason, Sandeep Nagra, Ram Malladi,
Andrew Peniket, Maria Gilleece, Rahuman Salim, Eleni Tholouli, Victoria
Potter, Charles Crawley, Rachel Protheroe, Anne Parker, KeithWilson, Jiri
Pavlu, Jenny Byrne, Richard Dillon, Naeem Khan, Sylvie D. Freeman
Data analysis and interpretation: Charles Craddock, Aimee Jackson, Justin
Loke, Shamyla Siddique, Andrea Hodgkinson, Georgia Andrew, Keith
Wheatley, Richard Dillon, Nicholas McCarthy, Sylvie D. Freeman
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
OS
Time From Transplant (months)






40 40 40 39 39 38 36 36 36 36 34 33 31 26 22 20 19 17 12
20 20 20 20 20 18 17 17 15 15 15 15 12 8 8 5 5 4 3
31 31 31 29 27 27 26 26 25 24 22 20 20 16 16 16 14 13 11






























85% (70 to 93)
CI
R
Time From Transplant (months)






40 40 40 40 40 37 34 34 33 33 33 32 29 25 22 20 18 16 11
20 20 20 19 18 15 14 14 13 12 12 12 10 7 7 5 5 4 3
31 31 31 29 27 27 25 24 24 24 23 21 20 17 17 17 15 14 11































FIG 4. (A) OS by month 3 Chimerism with pretransplant MRD status and (B) CIR by month 3 Chimerism with pretransplant MRD status. Outcomes are for
transplanted patients who were alive and relapse-free at day 1 100. MRD status is by conventional flow MRD. Negative—full, pretransplant MRD-negative
andmonth 3 full donor T-cell chimerism. Positive—full, pretransplant MRD-positive andmonth 3 full donor T-cell chimerism. Negative—mixed, pretransplant
MRD-negative and month 3 mixed donor T-cell chimerism. Positive—mixed, pretransplant MRD-positive and month 3 mixed donor T-cell chimerism. CIR,
Cumulative incidence of relapse; MRD, measurable residual disease; OS, overall survival.
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